Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJM199309163291222 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of interferon-alpha 1b injection into the intervertebral foramen with ultrasonic guidance in patients with postherpetic neuralgia: study protocol for a randomized, double-blind, placebo-controlled, multicenter clinical trial.
Front Neurol
January 2025
Department of Pain Medicine, China-Japan Friendship Hospital, Beijing, China.
Purpose: Postherpetic neuralgia (PHN) is a type of refractory neuropathic pain that causes significant suffering, disability, economic loss, and medical burden. In this study, we aim to evaluate the efficacy and safety of interferon (IFN)-α1b injection into the intervertebral foramen of patients with PHN.
Patients And Methods: This is a study protocol for a randomized, double-blind placebo-controlled multicenter clinical trial.
Evaluation of lignocaine HCl as a therapeutic and diagnostic tool in myofascial pain dysfunction syndrome and internal derangement.
Natl J Maxillofac Surg
November 2024
Department of Oral and Maxillofacial Surgery, S. N. Medical College, Agra, Uttar Pradesh, India.
Background: Myofascial pain syndrome MPS is one of the most common causes of chronic musculoskeletal pain. It clinically presents with hypersensitive points in the muscle called "trigger points". Most of the time it remains undiagnosed/undertreated and this leads to severity in symptoms.
View Article and Find Full Text PDFBackground: The primary objective of this study was to compare the efficacy of lignocaine-dexamethasone and lignocaine-triamcinolone infiltration, along the spinal-epidural needle insertion pathway, to prevent backache after lower abdominal surgeries.
Methods: This prospective, double-blind randomized controlled study included a total of 150 patients, scheduled for elective lower abdominal surgery under combined spinal-epidural (CSE) anaesthesia. The patients were randomised into three groups Group L (Lignocaine, n=50), Group DL (Dexamethasone, Lignocaine, n=50), and Group TL (Triamcinolone, Lignocaine, n=50).
Contribution of nebulized budesonide before bronchoscopy, a prospective clinical study.
Postgrad Med J
January 2025
Department of Respiratory and Critical Care Medicine, Tianjin University Chest Hospital, Thoracic Clinical College of Tianjin Medical University, Tianjin Chest Hospital, No. 261 Taier Zhuang Nan Road, Jinnan District, Tianjin 300051, China.
Purpose: This study evaluated the efficacy of adding budesonide to nebulized lidocaine in patients undergoing flexible bronchoscopy (FB) under topical anaesthesia.
Study Design: Patients aged ≥18 years, scheduled for FB under topical anaesthesia were randomized into two groups: the combination group received a pre-treatment of 2 ml 1 mg budesonide with 5 ml 2% lidocaine, whilst the lidocaine group received 5 ml 2% lidocaine with 2 ml saline solution, both administered via nebulization. Blood pressure (BP), heart rate, and percutaneous oxygen saturation were recorded before, during, and 10 min after FB.
Intra-arterial lidocaine administration of lidocaine in middle meningeal artery for short-term treatment of subarachnoid hemorrhage-related headaches.
Interv Neuroradiol
January 2025
Neuroradiology, The Royal London Hospital, Barts NHS Trust, London, UK.
Background And Purpose: We report short- and intermediate-term effects on headaches with intra-arterial injection of lidocaine in the middle meningeal artery in patients with severe headaches associated with subarachnoid hemorrhage.
Methods: We treated seven patients with intra-arterial lidocaine in doses up to 50 mg in each middle meningeal artery via a microcatheter bilaterally (except in one patient). We recorded the maximum intensity of headache (graded by 11-point numeric rating scale) prior to procedure and every day for the next 10 days or discharge, whichever came first.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!